| Drug ID: | Drug143 |
|---|---|
| Drug Name: | Minocycline |
| CID: | 54675783 |
| DrugBank ID: | DB01017 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06201793 |
| Molecular Formula: | C23H27N3O7 |
| Molecular Weight: | 457.5 g/mol |
| Isomeric SMILES: | CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C |
| Synonyms: | minocycline; 10118-90-8; Minocyclin; Minociclina; CL 59806; Minocyn; 7-Dimethylamino-6-demethyl-6-deoxytetracycline; (4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE; CHEBI:50694; FYY3R43WGO |
| Phase 0: | 3 |
| Phase 1: | 58 |
| Phase 2: | 105 |
| Phase 3: | 40 |
| Phase 4: | 52 |
| Description: | A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1138 | 54675783 | Minocycline | 949000 | rpsI | Escherichia coli K-12 | 14723559 | Inhibitor |
| dt1139 | 54675783 | Minocycline | 947793 | rpsD | Escherichia coli K-12 | 14723559 | Inhibitor |
| dt1140 | 54675783 | Minocycline | 3553 | IL1B | Homo sapiens (human) | Modulator | |
| dt1141 | 54675783 | Minocycline | 240 | ALOX5 | Homo sapiens (human) | Inhibitor | |
| dt1142 | 54675783 | Minocycline | 4318 | MMP9 | Homo sapiens (human) | Inhibitor | |
| dt1143 | 54675783 | Minocycline | 7422 | VEGFA | Homo sapiens (human) | Inhibitor | |
| dt1144 | 54675783 | Minocycline | 834 | CASP1 | Homo sapiens (human) | Negative modulator | |
| dt1145 | 54675783 | Minocycline | 836 | CASP3 | Homo sapiens (human) | Negative modulator | |
| dt1146 | 54675783 | Minocycline | 54205 | CYCS | Homo sapiens (human) | Negative modulator | |
| dt1147 | 54675783 | Minocycline | 5594 | MAPK1 | Homo sapiens (human) | 11986668 | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06201793 | Minocyclin in Ulcerative Colitis as Added on Therapy | PHASE2 | COMPLETED | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalazine|DRUG: Minocycline | Details |
| NCT00820365 | SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease | PHASE2 | COMPLETED | 4SC AG | Inflammatory Bowel Disease (IBD) | DRUG: SC12267 (4SC-101) | Details |
| NCT05573685 | Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training | NA | COMPLETED | Click Therapeutics, Inc. | Rheumatoid Arthritis|Diabetic Neuropathy|Fibromya… | DEVICE: DiNaMo Study App|DEVICE: Placebo App | Details |
| NCT07161297 | Remimazolam for Colonoscopy in IBD Patients | PHASE4 | NOT_YET_RECRUITING | Humanitas Clinical and Research Center | IBD (Inflammatory Bowel Disease) | DRUG: Intravenous remimazolam (5 mg initially, wi… | Details |
| NCT07156929 | Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation | NA | COMPLETED | University Hospital Schleswig-Holstein | Respiratory Infection (for Example, Pneumonia, Br… | DIETARY_SUPPLEMENT: Controlled-ileocolonic-releas… | Details |
| NCT05389709 | A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting | NULL | COMPLETED | Bayer | Functional Gastrointestinal Disorders Such as Irr… | DRUG: Iberogast (STW5-II, BAY98-7410) | Details |
| NCT05372939 | Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET) | PHASE2 | COMPLETED | Applied Molecular Transport | Ulcerative Colitis | DRUG: AMT-101 (oral)|OTHER: Placebo (oral)|COMBIN… | Details |
| NCT07428096 | A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease | PHASE1 | ACTIVE_NOT_RECRUITING | Palisade Bio | Fibrostenotic Crohn's Disease | DRUG: PALI-2108 | Details |
| NCT05117749 | Saffron and Ulcerative Colitis | PHASE2 | UNKNOWN | Shiraz University of Medical Sciences | Ulcerative Colitis | DRUG: Saffron 100|DRUG: Saffron 50|DRUG: Placebo | Details |
| NCT07421011 | Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers. | PHASE1 | RECRUITING | Valenta Pharm JSC | Irritable Bowel Syndrome|Gallstone Disease|GERD|B… | DRUG: Trimedat® | Details |
| NCT05076175 | A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis | PHASE2|PHASE3 | RECRUITING | Bristol-Myers Squibb | Colitis, Ulcerative | DRUG: Ozanimod | Details |
| NCT05058417 | Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis | PHASE2 | WITHDRAWN | Sadat City University | Ulcerative Colitis | DRUG: Empagliflozin 10 MG|DRUG: Placebo | Details |
| NCT04925973 | Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management | PHASE2 | ACTIVE_NOT_RECRUITING | McMaster University | Ulcerative Colitis Acute | DRUG: Tofacitinib 10 MG [Xeljanz] | Details |
| NCT07083193 | A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis | PHASE1|PHASE2 | RECRUITING | Accro Bioscience (Suzhou) Limited | Ulcerative Colitis | DRUG: AC-101 | Details |
| NCT04924114 | A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002) | PHASE1 | COMPLETED | Merck Sharp & Dohme LLC | Ulcerative Colitis | DRUG: MK-6194|DRUG: MK-6194-matching placebo | Details |
| NCT04883840 | Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis | PHASE2|PHASE3 | TERMINATED | Universitaire Ziekenhuizen KU Leuven | Ulcerative Colitis | DRUG: Rosuvastatin 10mg | Details |
| NCT04880876 | A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) | PHASE3 | ENROLLING_BY_INVITATION | AbbVie | Irritable Bowel Syndrome | DRUG: 25mg Eluxadoline|DRUG: 100mg Eluxadoline | Details |
| NCT07062185 | A Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ENC1018 Capsules in Patients With Moderate-to-severe Active Ulcerative Colitis (UC) | NA | NOT_YET_RECRUITING | Tang-Du Hospital | Ulcerative Colitis (UC) | DRUG: ENC1018 capsule administration group | Details |
| NCT04741087 | Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis | PHASE2 | COMPLETED | Applied Molecular Transport | Pouchitis | DRUG: AMT-101 (oral)-Dose A|DRUG: AMT-101 (oral)-… | Details |
| NCT04583358 | Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) | PHASE2 | UNKNOWN | Applied Molecular Transport | Ulcerative Colitis | DRUG: AMT-101 (oral)|OTHER: Placebo (oral) | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Minocycline Prevents the Development of Key Features of Inflammation and Pain i…
PMID: 36183969
Year: 2023
Relationship Type:
Treatment
Score: 9.5
Abdominal pain is a common feature in inflammatory bowel disease (IBD) patients, and greatly compromises their quality of life. Therefore, the identi…
Minocycline: far beyond an antibiotic
PMID: 23441623
Year: 2013
Relationship Type:
Treatment
Score: 9.1
Minocycline is a second-generation, semi-synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properti…
The intestinal anti-inflammatory effect of minocycline in experimental colitis …
PMID: 21193045
Year: 2011
Relationship Type:
Treatment
Score: 6.1
Comment in Inflamm Bowel Dis. 2011 Aug;17(8):1824. BACKGROUND: Reactivation of latent Mycobacterium tuberculosis (TB) is a rare, yet devastatin…